Basel, Switzerland – Feb 29, 2024, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, celebrates Rare Disease Day 2024 in support of the ANCA-associated vasculitis (AAV) and idiopathic pulmonary fibrosis (IPF) communities.
Rare Disease Day is observed every year on 28 February (or 29 in leap years), the rarest day of the year. Rare Disease Day is the globally-coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for the 300 million people worldwide living with a rare disease.
“We believe all people living with a rare disease should have equal opportunities. By sharing our colors, we can support and help raise awareness for those affected by rare diseases,” said Roberto Iacone, Chief Executive Officer of Alentis. “At Alentis we are working hard to progress our novel therapy for ANCA-associated vasculitis and idiopathic pulmonary fibrosis and we are glad to show our support to these communities on this important day.”
About ANCA-RPGN
ANCA-associated vasculitis with rapidly progressive glomerulonephritis (ANCA-RPGN) is a rare, severe and potentially fatal disease. RPGN is characterized by rapid loss of kidney function over a very short period (days to weeks). Despite potent immunosuppressive treatment, most patients develop significant or total loss of kidney function.
About IPF
IPF is a rare and serious chronic disease affecting tissue surrounding the air sacs or alveoli in the lungs, resulting in the thickening of lung tissue. Over time, this thickening causes permanent scarring of the lungs, called fibrosis, which makes breathing increasingly difficult. There is currently no cure for this condition with treatments only slowing the progression of IPF.
About lixudebart (ALE.F02)
Lixudebart is a first-in-class monoclonal antibody developed by Alentis for liver, lung and kidney fibrosis. It specifically targets a unique CLDN1 epitope exposed in fibrotic tissue to stop progression and even reverse disease. Lixudebart is an investigational antibody that was well tolerated and without any serious safety concerns in a Phase 1 single- and multiple-ascending dose study in healthy volunteers.
About Alentis Therapeutics
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering anti-CLDN1 antibodies to modify and reverse the course of disease.
Alentis was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). Alentis is headquartered in pharma-biotech hub Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US. Visit www.alentis.ch
For more information please contact:
Alentis Therapeutics
Sariette Witte
sariette.witte@alentis.ch
+41 78 245 7310